Cytoflavin in the Complex Rehabilitation of Stroke Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

Also called NCT05935787

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 240 participants (enrolled count) (from the registry)
Sponsor
POLYSAN Scientific & Technological Pharmaceutical Company (from the registry)
Registry
  • NCT NCT05935787
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05935787. Randomized; triple masking; primary purpose treatment. Start 2023-06-30 (actual); primary completion 2024-06-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cytoflavin in the Complex Rehabilitation of Stroke Patients
Condition
Stroke
Intervention (Drug)
Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)
Intervention (Drug)
Placebo
Lead sponsor
POLYSAN Scientific & Technological Pharmaceutical Company (class: industry)

Record details

Record id
cardio:ct-nct05935787
Content hash
03d56014263942e2136d626f24572fe388914949a447fdda4d14d475ec2404eb